Characteristics	Mutated IDH1 patients (n=15)		WT IDH1 patients (n=55)	
	Nb of patients	%	Nb of patients	%
Sex				
Female	5/15	33%	23/55	42%
Male	10/15	67%	32/55	58%
Age at diagnosis (years)				
Mean (SD)	40 (10.4)		60 (10.2)	
Range	[26-63]		[29-80]	
7p+/10q- (CNV)	0/13	0%	23/34	68%
unknowm status 7p10q	2/15	13%	21/55	38%
Tot 1p19q codeleted (FISH+INA+CNV)	9/14	64%	2/55	4%
unknowm status 1p19q	1/15	7%	0/55	0%
MGMT promoter methylation (>8%)	14/15	93%	25/55	45%
Resection				
Total	6/15	40%	23/55	42%
Partial	7/15	47%	31/55	56%
Large biopsy	2/15	13%	1/55	2%
Post-operative treatment				
R + TMZ = "Stupp"	5/15	34%	41/55	75%
Radiotherapy only	2/15	13%	3/55	5%
Chemotherapy only	4/15	27%	2/55	4%
No treatment	2/15	13%	4/55	7%
unknown	2/15	13%	5/55	9%
Overall survival (years)				
Median	Not reached		1.25	
Range	[0.1-6.6]		[0.1-3.8]	

Supplemental table S1: Demographic and molecular features of the 70 patients with glioma. Gain in Chromosome *7p* correlating with loss in Chromosome *10q* status (7p+/10q-) has been assessed by copy number variation study (CNV). The 1p19q codeletion status has been determined by merging data obtained by Fluorescence *in situ* hybridization (FISH), Internexin Immunostaining (INA) and CNV analyses. *MGMT* methylation is the mean of the methylation of five CpG sites located between the hg19 coordinates 131265507 to 131265526. "Stupp" post-operative treatment combined radiotherapy (R) with temozolomide (TMZ) chemotherapy. SD: standard deviation.